Fewer Episodes of Recurrence, So Why Expand This Heart Drug Trial? | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics Inc..

David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL), joins us to discuss an unexpected development in the company’s Phase III MAVERIC trial of CardiolRx, an investigational oral treatment for recurrent pericarditis.

The trial reached its original enrollment target ahead of schedule, but fewer disease recurrences than anticipated have prompted plans to add more patients. David explains how the expansion supports the statistical power needed to evaluate the treatment. The study remains blinded, so the observation does not yet establish that CardiolRx is responsible.

We also discuss earlier clinical findings, the differences between Cardiol’s approach and Novo Nordisk’s recent cardiovascular trials, and why David believes investors are misjudging the cardiac inflammation sector. He outlines the planned mid-2027 trial readout, the steps toward an FDA application if results support it, and the company’s expected cash runway into Q1 2028.

FULL DISCLOSURE: Cardiol Therapeutics Inc. is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cardiol Therapeutics Inc.. The author has been compensated to cover Cardiol Therapeutics Inc. on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics Inc.. Cardiol Therapeutics (TSX: CRDL) has...

Friday, September 25, 2026, 09:26:00 AM

Cardiol Therapeutics Announces US Listing

Cardiol Therapeutics (TSX: CRDL; OTCMKTS: CRTPF) announced this morning that it has qualified to trade...

Thursday, May 30, 2019, 09:43:44 AM

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

In this interview David Elsley, CEO of Cardiol Therapeutics (NASDAQ: CRDL) (TSXV: CRDL), shares some...
Monday, August 18, 2025, 03:53:00 PM

Cardiol Enters Into Supply Agreement With Shoppers Drug Mart

Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by...

Wednesday, March 18, 2020, 03:27:03 PM

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

In this conversation with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL)...
Sunday, April 19, 2026, 09:24:00 AM